Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia
Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia
Recruiting · NCT05592015 · Registry updated 2026-10-01Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia | Hemic and Lymphatic Diseases, Leukemia, Large Granular Lymphocytic, Neoplasms by Histologic Type, T-cell leukemia, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 2 | 2026-10-01 | NCT05592015 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Jonathan Brammer | 3 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Dana-Farber Cancer Institute | Boston | United States | 626 |
| Memorial Sloan Kettering Cancer Center | New York | United States | 1000 |
| Ohio State University Comprehensive Cancer Center | Columbus | United States | 548 |